Skip to main content
. 2020 Aug 5;5(11):1255–1262. doi: 10.1001/jamacardio.2020.2981

Figure 1. Kaplan-Meier Rates for the Primary End Point (a Composite of Cardiovascular [CV] Death, Myocardial Infarction [MI], or Stroke) by Guideline-Derived Atherosclerotic Cardiovascular Disease (ASCVD) Risk Group and High-Sensitivity Troponin I (hsTnI) Level.

Figure 1.

A, Patients meeting clinical criteria for the very high-risk ASCVD group had a statistically significantly higher rate of CV death, MI, or stroke, with a 3-year Kaplan-Meier event rate of 8.8% compared with 5.0% in the lower-risk ASCVD group (hazard ratio [HR], 2.01; 95% CI, 1.58-2.57; P < .001). B, Stratifying those with hsTnI levels of 6 ng/L or less into undetectable (<2 ng/L) and low (2-6 ng/L) levels identified patients with 3-year event rates of 2.8% and 6.0%, respectively, with a 3-year event rate of 13.5% in patients with hsTnI levels exceeding 6 ng/L. In the adjusted regression model, compared with patients with undetectable hsTnI levels, those with hsTnI levels of 2 to 6 ng/L were at a more than 2-fold higher risk (adjusted HR, 2.38; 95% CI, 1.47-3.85; P < .001) of adverse events, and those with hsTnI levels exceeding 6 ng/L were at an almost 5-fold higher risk (adjusted HR, 4.83; 95% CI, 2.98-7.84; P < .001).